Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate
Conditions
Interventions
MM-093
Locations
20
United States
Montgomery Rheumatology Associates
Montgomery, Alabama, United States
East Valley Rheumatology & Osteoporosis
Gilbert, Arizona, United States
Radiant Research
Scottsdale, Arizona, United States
Arthritis Medical Center of the Central Coast
Santa Maria, California, United States
National Jewish Medical and Research Center
Denver, Colorado, United States
Denver Arthritis Clinic
Denver, Colorado, United States
Start Date
February 1, 2007
Last Updated
March 27, 2008
NCT06647069
NCT07484243
NCT06841562
NCT07268326
NCT07029555
NCT07233655
Lead Sponsor
Merrimack Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions